The National Hemophilia Foundation (NHF) states that 1 in 5,000 people are affected by Hemophilia A. This genetic deficiency is about four times common than type B. It would further affect the global point-of-care coagulation (POC) testing devices market positively in the forthcoming years. This information is published in an upcoming study by Fortune Business Insights, titled, “Point-of-Care Coagulation (POC) Testing Devices Market Size, Share and Global Trend By Type (Prothrombin Time/International Normalized Ratio (PT-INR) Testing devices, Bleeding Time Testing devices, Fibrinogen Level Testing devices), By End User (Hospitals, Clinics) and Geography Forecast till 2026.”
The report covers the growth prospects and the current scenario of the global point-of-care coagulation (POC) testing devices market for the period of 2019-2026. To obtain the exact size of the market, the report offers an elaborate theory of the global market by summation, synthesis, and study of data from numerous significant sources.
Browse Complete Report:
Fortune Business Insights has listed some of the prominent market players operating in the global point-of-care coagulation (POC) market. They are as follows:
- Sysmex Corporation
- Siemens Healthcare GmbH
- Hoffmann-La Roche Ltd.
- Accriva Diagnostics
- Helena Laboratories
- Other key market players
Increasing Number of Surgical Procedures Worldwide to Boost Market Growth
The report mentions that a rise in the technological advancements in the field of point-of-care coagulation (POC) testing devices is projected to propel the global market growth. Furthermore, increasing demand for preventive medical care, growing prevalence of bleeding disorders, and clinical advantages of POC testing devices will propel the global point-of-care coagulation (POC) testing devices market during the forecast period. Combined with this, increasing usage of coagulants and rising number of surgical procedures will drive the market growth.
Increasing Number of Research and Development Activities to Favor Growth in Asia Pacific
The global point-of-care coagulation (POC) testing devices market is geographically grouped into North America, the Middle East and Africa, Latin America, Europe, and Asia Pacific. Amongst these regions, North America was in the leading position in the global point-of-care coagulation (POC) testing devices market in the year 2018. According to Fortune Business Insights, Asia Pacific and North America are likely to exhibit a staggering CAGR in the forthcoming years driven by numerous factors, such as well-established healthcare infrastructure, increasing access to technologically advanced devices, rising incidence of bleeding disorders, high healthcare expenditure, and rising number of surgical procedures. Moreover, several prominent key players are investing huge sums in the research and development activities of POC testing.
There is also a rise in the demand for preventive medical care. The Middle East and Africa and Latin America, on the other hand, are anticipated to exhibit a comparatively lower CAGR during the forecast period.
Get Sample PDF:
Prominent Key Players Focus on Innovative Product Launches and Strategic Collaborations to Strengthen Position in Market
Siemens, a multinational conglomerate company, based in Germany, announced the launch of its new Xprecia Stride Coagulation Analyzer in May 2015. It aids in providing reliable and fast Prothrombin time testing (PT/INR) for managing and monitoring oral anticoagulation therapy (OAT). The analyzer was declared a winner of the “Red Dot Award: Product Design for 2015”. It consists of numerous features and innovations. Xprecia weighs only 300 grams and hence, one can hold it at any angle. The clinician can directly bring it to the patient’s finger for comfortable and efficient application of blood sample. To aid in raising usability and workflow efficiency, a bar-code scanner is provided to simplify data capture that would further aid in the calibration of a new lot before testing begins.
In September 2019, Instrumentation Laboratory (IL), a manufacturer and provider of diagnostic solutions, based in the U.S., declared that it was awarded an agreement by Premier, for point-of-care (POC) coagulation and patient blood management (PBM). The new agreement enables the members of Premier to take all the benefits of terms and special pricing for the Hemochron Signature Elite whole-blood Hemostasis system, VerifyNow platelet-reactivity system, and ROTEM delta viscoelastic testing system. All the three products complement the recently signed contract between Premier and IL for GEM Premier blood gas system. They are also a part of the IL Acute Care Diagnostics portfolio. Premier is considered to be one of the first organization to own all four IL products on contract.
Speak to Analyst:
View Related Reports:
TUNA FISH MARKET 2019 SHARE GROWING RAPIDLY WITH RECENT TRENDS, DEVELOPMENT, REVENUE, DEMAND AND FORECAST TO 2026